PARP inhibitors have demonstrated antitumor efficacy in solid tumors, including pancreatic ductal adenocarcinoma (PDAC) characterized by homologous recombination deficiency (HRD). This evidence concerns the gene PARP1 and hypoparathyroidism-retardation-dysmorphism syndrome.